Journal
ANNALS OF ONCOLOGY
Volume 26, Issue 8, Pages 1573-1588Publisher
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdv187
Keywords
non-small-cell lung cancer; locally advanced; stage III; recommendations; ESMO
Categories
Funding
- Pfizer
- Roche
- Boehringer Ingelheim
- AstraZeneca
- Eli-Lilly Chair in Respiratory Oncology at the Leuven University
- AstraZeneca Chair in Personalised Lung Cancer Care at the Leuven University
- Eli Lilly
- Genentech
- Lilly
- Endocyte
- Novartis
- Varian Medical Systems
- Covidien
- ScreenCell
- PointHope
- Merck Serono
- Cancer Research UK [20465] Funding Source: researchfish
Ask authors/readers for more resources
To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines of treatment in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on locally advanced disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available